Investigation Report on China Recombinant Factor Market, 2010-2019
Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor or Ⅸ, though not rare, which affects mostly males. Hemophilia A (clotting factor deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor while over half are in severe conditions.
Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor too.
After entering China, recombinant factor develops fast with annual sales value rising from less than CNY 6 million in 2009 to CNY 93.78 million in 2014 and CAGR reaching up to 76.8% during 2009-2014. Currently, recombinant factor in the Chinese market are all imported drugs. They mainly come from the following three companies: Baxter Bioscience Manufacturing (SW), Wyeth Farma S.A. (SP) and Bayer (the US), among which Bayer (the US) has the largest market share of 57.40% by sales value in 2014.
As hemophiliacs’ ability to pay for medical treatment keeps increasing due to economic development, the market size of recombinant factor in China is expected to keep expanding.
Readers can get at least the following information from this report:
sales status of recombinant factor in China
price of recombinant factor in Chinese market
major manufacturers of recombinant factor in Chinese market
share of dosage forms of recombinant factor in China
market outlook of recombinant factor in China
The author suggests the following groups of people purchase this report:
manufacturers of blood products
investors/ research institutions interested in China blood products market
any interest in the Chinese medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed